PACIFIC BIOSCIENCES OF CALIF (PACB) Fundamental Analysis & Valuation

NASDAQ:PACB • US69404D1081

Current stock price

1.38 USD
+0.06 (+4.55%)
Last:

This PACB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PACB Profitability Analysis

1.1 Basic Checks

  • In the past year PACB has reported negative net income.
  • In the past year PACB has reported a negative cash flow from operations.
  • PACB had negative earnings in each of the past 5 years.
  • PACB had a negative operating cash flow in each of the past 5 years.
PACB Yearly Net Income VS EBIT VS OCF VS FCFPACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M -400M -500M

1.2 Ratios

  • PACB has a worse Return On Assets (-69.68%) than 89.29% of its industry peers.
  • PACB's Return On Equity of -10214.54% is on the low side compared to the rest of the industry. PACB is outperformed by 92.86% of its industry peers.
Industry RankSector Rank
ROA -69.68%
ROE -10214.54%
ROIC N/A
ROA(3y)-37.28%
ROA(5y)-27.73%
ROE(3y)-3439.82%
ROE(5y)-2079.63%
ROIC(3y)N/A
ROIC(5y)N/A
PACB Yearly ROA, ROE, ROICPACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

1.3 Margins

  • Looking at the Gross Margin, with a value of 33.97%, PACB is doing worse than 64.29% of the companies in the same industry.
  • In the last couple of years the Gross Margin of PACB has declined.
  • The Profit Margin and Operating Margin are not available for PACB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.74%
GM growth 5Y-5.45%
PACB Yearly Profit, Operating, Gross MarginsPACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. PACB Health Analysis

2.1 Basic Checks

  • PACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for PACB has been increased compared to 1 year ago.
  • PACB has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for PACB is higher compared to a year ago.
PACB Yearly Shares OutstandingPACB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
PACB Yearly Total Debt VS Total AssetsPACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • Based on the Altman-Z score of -4.52, we must say that PACB is in the distress zone and has some risk of bankruptcy.
  • PACB's Altman-Z score of -4.52 is on the low side compared to the rest of the industry. PACB is outperformed by 85.71% of its industry peers.
  • A Debt/Equity ratio of 120.65 is on the high side and indicates that PACB has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 120.65, PACB is doing worse than 92.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 120.65
Debt/FCF N/A
Altman-Z -4.52
ROIC/WACCN/A
WACC6.71%
PACB Yearly LT Debt VS Equity VS FCFPACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 5.15 indicates that PACB has no problem at all paying its short term obligations.
  • PACB has a Current ratio of 5.15. This is amongst the best in the industry. PACB outperforms 82.14% of its industry peers.
  • A Quick Ratio of 4.47 indicates that PACB has no problem at all paying its short term obligations.
  • PACB has a better Quick ratio (4.47) than 82.14% of its industry peers.
Industry RankSector Rank
Current Ratio 5.15
Quick Ratio 4.47
PACB Yearly Current Assets VS Current LiabilitesPACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PACB Growth Analysis

3.1 Past

  • PACB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.59%.
  • The Revenue has been growing slightly by 3.89% in the past year.
  • The Revenue has been growing by 15.19% on average over the past years. This is quite good.
EPS 1Y (TTM)-11.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.51%
Revenue 1Y (TTM)3.89%
Revenue growth 3Y7.64%
Revenue growth 5Y15.19%
Sales Q2Q%13.82%

3.2 Future

  • PACB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.88% yearly.
  • PACB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.31% yearly.
EPS Next Y71.86%
EPS Next 2Y33.11%
EPS Next 3Y21.69%
EPS Next 5Y12.88%
Revenue Next Year10.42%
Revenue Next 2Y11.41%
Revenue Next 3Y12.47%
Revenue Next 5Y11.31%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PACB Yearly Revenue VS EstimatesPACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
PACB Yearly EPS VS EstimatesPACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. PACB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PACB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PACB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PACB Price Earnings VS Forward Price EarningsPACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PACB indicates a rather cheap valuation: PACB is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.51
PACB Per share dataPACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PACB's earnings are expected to grow with 21.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.11%
EPS Next 3Y21.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PACB Dividend Analysis

5.1 Amount

  • No dividends for PACB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PACB Fundamentals: All Metrics, Ratios and Statistics

PACIFIC BIOSCIENCES OF CALIF

NASDAQ:PACB (4/1/2026, 9:53:08 AM)

1.38

+0.06 (+4.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-07
Inst Owners59.46%
Inst Owner Change9.27%
Ins Owners0.75%
Ins Owner Change9.25%
Market Cap416.76M
Revenue(TTM)160.00M
Net Income(TTM)-546.38M
Analysts76.25
Price Target2.3 (66.67%)
Short Float %15.14%
Short Ratio6.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.2%
Min EPS beat(2)16.15%
Max EPS beat(2)20.24%
EPS beat(4)3
Avg EPS beat(4)-147.83%
Min EPS beat(4)-646.96%
Max EPS beat(4)20.24%
EPS beat(8)4
Avg EPS beat(8)-111.78%
EPS beat(12)6
Avg EPS beat(12)-72.52%
EPS beat(16)7
Avg EPS beat(16)-55.37%
Revenue beat(2)1
Avg Revenue beat(2)-1.68%
Min Revenue beat(2)-6.27%
Max Revenue beat(2)2.91%
Revenue beat(4)3
Avg Revenue beat(4)1.4%
Min Revenue beat(4)-6.27%
Max Revenue beat(4)5.6%
Revenue beat(8)3
Avg Revenue beat(8)-3.79%
Revenue beat(12)6
Avg Revenue beat(12)0.65%
Revenue beat(16)7
Avg Revenue beat(16)-0.16%
PT rev (1m)-7.35%
PT rev (3m)-2.7%
EPS NQ rev (1m)6.76%
EPS NQ rev (3m)5.21%
EPS NY rev (1m)2.91%
EPS NY rev (3m)1.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.21%
Revenue NY rev (1m)-1.1%
Revenue NY rev (3m)-1.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.6
P/FCF N/A
P/OCF N/A
P/B 77.91
P/tB N/A
EV/EBITDA 1.51
EPS(TTM)-1.83
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.53
BVpS0.02
TBVpS-1.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.68%
ROE -10214.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.97%
FCFM N/A
ROA(3y)-37.28%
ROA(5y)-27.73%
ROE(3y)-3439.82%
ROE(5y)-2079.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.74%
GM growth 5Y-5.45%
F-Score3
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 120.65
Debt/FCF N/A
Debt/EBITDA 2.93
Cap/Depr 2.02%
Cap/Sales 4.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.15
Quick Ratio 4.47
Altman-Z -4.52
F-Score3
WACC6.71%
ROIC/WACCN/A
Cap/Depr(3y)20.63%
Cap/Depr(5y)60.61%
Cap/Sales(3y)4.42%
Cap/Sales(5y)6.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.51%
EPS Next Y71.86%
EPS Next 2Y33.11%
EPS Next 3Y21.69%
EPS Next 5Y12.88%
Revenue 1Y (TTM)3.89%
Revenue growth 3Y7.64%
Revenue growth 5Y15.19%
Sales Q2Q%13.82%
Revenue Next Year10.42%
Revenue Next 2Y11.41%
Revenue Next 3Y12.47%
Revenue Next 5Y11.31%
EBIT growth 1Y39.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.67%
EBIT Next 3Y21.97%
EBIT Next 5YN/A
FCF growth 1Y43.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.03%
OCF growth 3YN/A
OCF growth 5YN/A

PACIFIC BIOSCIENCES OF CALIF / PACB Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PACIFIC BIOSCIENCES OF CALIF (PACB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PACB.


What is the valuation status of PACIFIC BIOSCIENCES OF CALIF (PACB) stock?

ChartMill assigns a valuation rating of 1 / 10 to PACIFIC BIOSCIENCES OF CALIF (PACB). This can be considered as Overvalued.


What is the profitability of PACB stock?

PACIFIC BIOSCIENCES OF CALIF (PACB) has a profitability rating of 0 / 10.